Genentech Sticks To Script When Responding to Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s next line will likely involve a sweeter offer.
You may also be interested in...
Genentech/Roche: The End Of An Era
Roche offers to buy out Genentech’s minority stakeholders for $89 per share, or $43.7 billion, to create the seventh largest U.S. pharma company.
Roche Finally Gets A Nod With $3.4 Billion Bid For Ventana
After seven months and a half dozen attempts to acquire the diagnostics company, Roche wins over Ventana’s board with a sweetened bid .
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.